Glyconanoparticle Cytotoxicity Assay Service
Overview
Glyconanoparticles exhibit multifaceted effects and hold significant promise in drug delivery and bioimaging. They integrate the benefits of a nano drug delivery system with the multivalent interactions of sugars, thereby significantly enhancing drug targeting capabilities. Assessing their cytotoxic effects is crucial for researchers to evaluate their safety and effectiveness in biomedical applications. CD BioGlyco has a well-established GlycoNano™ Platform and offers a comprehensive glyconanoparticle cytotoxicity assay service.
Empowering Glyconanoparticle Cytotoxicity Assay Through Cutting-edge Technologies
We have established a comprehensive Preclinical Study system for glyconanoparticles to help advance its use in biomedical applications. The entire program is executed through the following workflow to comprehensively assess the in vitro cytotoxicity of glyconanoparticle:
Glyconanoparticle Development
We are well-versed in various glyconanoparticle preparation methods and develop fucose, lactose, and galactose residue-modified glyconanoparticles, among others. Then we separate glyconanoparticles from unreacted substances and excess reagents by size exclusion chromatography, dialysis, etc., for purification. The products are characterized in detail by nuclear magnetic resonance (NMR), dynamic light scattering (DLS), scanning electron microscopy (SEM), and other technologies.
Cytotoxicity Assay
We assessed the cytotoxic effects of glyconanoparticles on different cell lines, including cell viability, proliferation, and morphology after exposure to glyconanoparticles. Appropriate controls, concentrations, and exposure times are selected based on various study objectives. Specific processes include the following:
- Cell line culture
Cancer and normal cells expressing target antigens are cultured for glyconanoparticle cytotoxicity analysis. We have experience with virtually all types of culture formats and meet a wide range of experimental needs.- Cancer cell lines (e.g. HeLa, MCF-7, A549)
- Primary human cells (e.g. HUVECs, HMSCs)
- Other cell types
- Detection
Cytotoxicity assays measure changes in a range of indicators including mitochondrial function, cell proliferation, cell viability, phospholipid deposition/lipid denaturation, DNA damage, and cell cycle. Through a series of assays, we determine the optimal exposure time (e.g. 24, 48, or 72 hours). Positive and negative controls are set up throughout the process to ensure the reliability of the assay.MTT assay The method measures cell viability based on metabolic activity. Flow cytometry It provides a rapid and reliable method to quantify viable cells in cell suspension. lactatedehydrogenase (LDH) assay This method is used to detect cell membrane integrity and cytotoxicity. XTT assay The method is used to assay mitochondrial dehydrogenase activity in living cells. Annexin V/PI staining This method is one of the most sensitive, efficient, and proven methods for the detection of apoptotic cells. Morphological observations It uses microscopy to detect apoptosis by morphology.
Data Analysis
The percentage of cell viability, etc., is calculated based on experimental data. We compile and analyze the data collected from these analyses using appropriate software packages.
Experimental Delivery
- Detailed description of the experimental methodology
- A synthesis of results and conclusions.
- Graphical representation of data (e.g., cell viability chat)
Workflow
We offer a one-stop glyconanoparticle cytotoxicity assay service. This process includes customized experimental design to meet your specific research needs and comprehensive interpretation of results. We will also discuss the results with you to gain insights and understand the implications of your study.

Applications
- The glyconanoparticle cytotoxicity assay is essential for the development of safe and efficient targeted drug delivery systems.
- The glyconanoparticle cytotoxicity assay is used to explore safer and more effective nanomedicines and therapeutics.
- The glyconanoparticle cytotoxicity assay is essential for the development of biosensors for the detection of various biomolecules.
Advantages
- We provide pre-sales consulting services to help you explore glyconanoparticles and design related experiments efficiently.
- Our experienced researchers customize the experimental process according to different experimental requirements and provide excellent after-sales service.
- Strict quality control processes, including validation of assays, positive and negative controls, etc., ensure reliable and reproducible results.
Publication Data
Technology: Cytotoxicity assay
Journal: Chemical Science
IF: 9.063
Published: 2017
Results: In this study, a multicomponent delivery system based on carbohydrate-functionalized gold nanoparticles conjugated to fluorophores or prodrugs was developed and cellular experiments were utilized to assess the potential applicability of the system as a bioimaging and drug delivery model. The results showed that the system could be used for drug-specific delivery and was more selective for HepG2 cells than HeLa and NIH3T3 cells. Validation with camptothecin (CPT) as a model drug revealed that Au-Gal-BA (CPT) exhibited similar cytotoxicity, excellent specificity, and superior biocompatibility for HepG2 cells. This study provides a reliable strategy for cell-type-specific trafficking.
Fig.1 Comparison of HepG2, NIH3T3, and HDF cell survival rates. (Wu, et al., 2017)
Frequently Asked Questions
- What cell types are used in the cytotoxicity assay?
We have a variety of cell lines for the glyconanoparticle cytotoxicity assay, including, but not limited to, cancer cell lines, primary cells, and immortalized cell lines. Common cell choices include HeLa, MCF-7, NIH 3T3, etc. Please communicate with us for detailed analysis requirements. - What kind of results do I get from a cytotoxicity assay?
Our cytotoxicity assay reports include comprehensive data on cell viability, dose-response curves, and cytotoxic effects. In addition, the assay report contains statistical analysis and interpretation of results to assist you in your glyconanoparticle preclinical studies. - How do I submit samples for testing?
After communicating about a specific glyconanoparticle cytotoxicity assay project, we will provide you with a detailed sample submission protocol, including shipping instructions and the necessary documentation to guide the sample collection, storage, and shipment according to our specifications for optimal results.
CD BioGlyco provides a high-quality glyconanoparticle cytotoxicity assay service to help explore its safety and application in therapeutic and diagnostic approaches. If you are interested in our glyconanoparticle cytotoxicity assay service, please feel free to contact us with specific information, such as the type of cells you are interested in or any other special requirements, to develop a solution. We look forward to assisting you in a wide range of glyconanoparticle research endeavors!
Reference
- Wu, X.; et al. Stimuli-responsive multifunctional glyconanoparticle platforms for targeted drug delivery and cancer cell imaging. Chemical Science. 2017, 8(5): 3980-3988.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




